|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors.
|
18713757 |
2008 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors.
|
18713757 |
2008 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1.
|
17941827 |
2008 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
FHL2 regulates cell cycle-dependent and doxorubicin-induced p21Cip1/Waf1 expression in breast cancer cells.
|
17682292 |
2007 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women.
|
16804901 |
2006 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.
|
17062672 |
2006 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
TNFalpha resistance in MCF-7 breast cancer cells is associated with altered subcellular localization of p21CIP1 and p27KIP1.
|
15592362 |
2005 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Endothelial p21(WAF1/CiP1) cell cycle inhibitor is down-regulated in breast cancer.
|
16080520 |
2005 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These in vitro responses were compared with expression responses in breast tumors sampled before and after treatment with doxorubicin or 5-fluorouracil/mitomycin C. The in vivo data corroborated the cell-type-specific responses to chemotherapeutics observed in vitro, including the induction of p21(waf1).
|
15205334 |
2004 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1).
|
15171713 |
2004 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer.
|
15161699 |
2004 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients.
|
15173090 |
2004 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
The 3'-untranslated region of p21WAF1 mRNA is a composite cis-acting sequence bound by RNA-binding proteins from breast cancer cells, including HuR and poly(C)-binding protein.
|
12431987 |
2003 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
LHGDN |
3,3'-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression.
|
12151347 |
2002 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer.
|
11872638 |
2002 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, mutations in the WAF1 gene are rare in tumors with or without p53 mutations, suggesting that except in a minor population of breast cancer patients of Caucasian origin, cell cycle dysregulation by mutated p53 or WAF1 genes may not contribute to breast tumor initiation or progression.
|
9815858 |
1997 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Then, we used this strategy to study the p53 activity in 23 primary breast tumours. p21(WAF1/CIP1 accumulation was detected in all tumours expressing wild-type TP53.
|
9010231 |
1997 |